Embodiments of the disclosure include coatings comprising an oligomerized polyphenol layer. The oligomerized polyphenol layer can be used as an intermediate coated layer on a medical device that hydrogen bonds to a synthetic or natural polymer, which in turn can be used as a top coat or further associated with another coated layer. The multilayered coatings can provide properties such as hemocompatibility or lubricity. In other embodiments, the oligomerized polyphenol layer is used on a medical device as a hemostatic layer configured to contact blood and promote coagulation. The oligomerized polyphenol layer can also be used on the inner surface (e.g., inner diameter) of a medical device to prevent bacterial adherence. The oligomerized polyphenol layer can also be used on the surface of a in vitro diagnostic article, or a cell culture device to, promote adsorption of a biological mo lecule.

Embodiments described herein relate to combinatorial compositions and uses thereof, for example, as vaccine adjuvant compositions, for enhancing immune response, for inducing differentiation of nave T cells to differentiate into IFN-γ-producing T cells, and for preventing and treating infections. The combinatorial composition comprises TLR and CLR agonists. The combinatorial composition comprises at least one TLR4 agonist and at least one Dectin-1 agonist, wherein the at least TLR4 agonist is monophosphoryl lipid A (MPLA) or glycopyranosyl lipid A (GLA), or the combinatorial composition comprises at least one TLR7/8 agonist and at least one Mincle agonist.

Embodiments described herein relate to combinatorial compositions and uses thereof, for example, as vaccine adjuvant compositions, for enhancing immune response, for inducing differentiation of nave T cells to differentiate into IFN-γ-producing T cells, and for preventing and treating infections. The combinatorial composition comprises TLR and CLR agonists. The combinatorial composition comprises at least one TLR4 agonist and at least one Dectin-1 agonist, wherein the at least TLR4 agonist is monophosphoryl lipid A (MPLA) or glycopyranosyl lipid A (GLA), or the combinatorial composition comprises at least one TLR7/8 agonist and at least one Mincle agonist.

The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.

The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.

A self-assembled gel composition with enhanced adhesion to cartilage tissue is provided. A cationic agent co-self assembles with a generally regarded as safe (GRAS), low molecular weight (<2,500 Da) gelator, forming homogeneous self-supporting gel that can encapsulate one or more therapeutic agents for controlled release. The composition adheres to connective tissue, e.g., cartilage, to a greater extent and a greater length of time than a self-assembled gel from gelators alone. The composition is used to specifically target connective tissue and deliver one or more therapeutic, prophylactic, or diagnostic agents for controlled release to improve dosing efficacy.

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (PSC), (3) non-alcoholic fatty liver disease (NAFLD), (4) sickle cell disease (SCD), (5) age-related macular degeneration (AMD), and (6) neurodegenerative disease, including, Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, Bi-polar Syndrome, traumatic brain injury, peripheral neuropathy, and Multiple Sclerosis (MS). Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions for their administration.

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (PSC), (3) non-alcoholic fatty liver disease (NAFLD), (4) sickle cell disease (SCD), (5) age-related macular degeneration (AMD), and (6) neurodegenerative disease, including, Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, Bi-polar Syndrome, traumatic brain injury, peripheral neuropathy, and Multiple Sclerosis (MS). Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions for their administration.

Twelve evidence-based hypotheses form the theory of brain aging, herein referred to as Brain Theory. Herein proposed are bioactive, neuro-available substances that, in coaction, work duly to mitigate specific molecular mechanisms of brain aging and enhance cognitive function based on a respective Brain Theory hypothesis.

Brain Theory hypotheses are the following: (1) Neurological Reserve, (2) Reductive-Oxidative Stress, (3) Caloric Restriction Anti-Inflammation, (4) Homocysteine Metabolism, (5) Neurotransmitter Neuroplasticity, (6) Telomere Mortality, (7) Immunosenescence, (8) Proteinopathy, (9) Glymphatic Dysfunction, (10) Circadian Clock Epigenetics, (11) Calcium-Dependent Synaptic Plasticity, and the (12) Gut-Brain-Axis.

BrainTheory™ N.sup.o 12 is a nocturnal dietary supplement formulated with evidence-based bioactive, neuro-available substances that modulate specific mechanisms of brain aging based on Brain Theory hypotheses. Substances in order of representative hypotheses are the following: (1) R-Alpha Lipoic Acid, (2) Crocetin, (3) Curcumin, (4) Methylcobalamin or Choline, (5) 5-Methyltetrahydrofolate or Eucommia ulmoides Oliver, (6) Trans-Pterostilbene, (7) Cholecalciferol or Omega-3 Fatty Acid Compound, (8) Apigenin, (9) Luteolin, (10) Melatonin, (11) Magnesium L-Threonate, and (12) Apple Pectin Prebiotic. Substances additionally have evidence-based cognitive enhancement properties akin to those of a nootropic agent.

A dietary supplement formulation duly purposed to modulate healthspan-related biological brain aging and demonstrate nootropic effects is not previously described.

Twelve evidence-based hypotheses form the theory of brain aging, herein referred to as Brain Theory. Herein proposed are bioactive, neuro-available substances that, in coaction, work duly to mitigate specific molecular mechanisms of brain aging and enhance cognitive function based on a respective Brain Theory hypothesis.

Brain Theory hypotheses are the following: (1) Neurological Reserve, (2) Reductive-Oxidative Stress, (3) Caloric Restriction Anti-Inflammation, (4) Homocysteine Metabolism, (5) Neurotransmitter Neuroplasticity, (6) Telomere Mortality, (7) Immunosenescence, (8) Proteinopathy, (9) Glymphatic Dysfunction, (10) Circadian Clock Epigenetics, (11) Calcium-Dependent Synaptic Plasticity, and the (12) Gut-Brain-Axis.

BrainTheory™ N.sup.o 12 is a nocturnal dietary supplement formulated with evidence-based bioactive, neuro-available substances that modulate specific mechanisms of brain aging based on Brain Theory hypotheses. Substances in order of representative hypotheses are the following: (1) R-Alpha Lipoic Acid, (2) Crocetin, (3) Curcumin, (4) Methylcobalamin or Choline, (5) 5-Methyltetrahydrofolate or Eucommia ulmoides Oliver, (6) Trans-Pterostilbene, (7) Cholecalciferol or Omega-3 Fatty Acid Compound, (8) Apigenin, (9) Luteolin, (10) Melatonin, (11) Magnesium L-Threonate, and (12) Apple Pectin Prebiotic. Substances additionally have evidence-based cognitive enhancement properties akin to those of a nootropic agent.

A dietary supplement formulation duly purposed to modulate healthspan-related biological brain aging and demonstrate nootropic effects is not previously described.